Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

Michael Miller(Clark University), Eugene Braunwald(Mass General Brigham), Kausik K. Ray(Imperial College London), Jie Qin(Brigham and Women's Hospital), Christopher P. Cannon(Brigham and Women's Hospital), Sabina A. Murphy(Brigham and Women's Hospital)
Journal of the American College of Cardiology
February 1, 2008
10.1016/j.jacc.2007.10.038
Cited by 614

Related Papers

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k